Critical Contrast: Prourocare Medical (OTCMKTS:PUMD) and BeyondAirInc . (OTCMKTS:XAIR)

Share on StockTwits

BeyondAirInc . (NASDAQ:XAIR) and Prourocare Medical (OTCMKTS:PUMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for BeyondAirInc . and Prourocare Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeyondAirInc . 0 0 1 0 3.00
Prourocare Medical 0 0 0 0 N/A

BeyondAirInc . currently has a consensus price target of $9.00, indicating a potential upside of 26.58%. Given BeyondAirInc .’s higher probable upside, equities analysts clearly believe BeyondAirInc . is more favorable than Prourocare Medical.

Valuation and Earnings

This table compares BeyondAirInc . and Prourocare Medical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BeyondAirInc . $7.72 million 13.49 -$6.56 million ($0.84) -8.46
Prourocare Medical N/A N/A N/A N/A N/A

Prourocare Medical has lower revenue, but higher earnings than BeyondAirInc ..

Profitability

This table compares BeyondAirInc . and Prourocare Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BeyondAirInc . -203.22% -176.57% -102.97%
Prourocare Medical N/A N/A N/A

Risk and Volatility

BeyondAirInc . has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, Prourocare Medical has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of BeyondAirInc . shares are held by institutional investors. 18.1% of BeyondAirInc . shares are held by company insiders. Comparatively, 29.3% of Prourocare Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Prourocare Medical beats BeyondAirInc . on 5 of the 9 factors compared between the two stocks.

BeyondAirInc . Company Profile

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

Prourocare Medical Company Profile

ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.

Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Raymond James Reiterates C$2.50 Price Target for Champion Iron
Raymond James Reiterates C$2.50 Price Target for Champion Iron
CAE  PT Lowered to C$23.00
CAE PT Lowered to C$23.00
Bonterra Energy  PT Lowered to C$1.50
Bonterra Energy PT Lowered to C$1.50
CIBC Lowers Air Canada  Price Target to C$29.00
CIBC Lowers Air Canada Price Target to C$29.00
Deutsche Bank Reiterates CHF 17 Price Target for ABB
Deutsche Bank Reiterates CHF 17 Price Target for ABB
Chorus Aviation  Price Target Cut to C$4.25
Chorus Aviation Price Target Cut to C$4.25


 
© 2006-2020 Zolmax.